Accumulated Other Comprehensive Income (Loss), Net of Tax of KalVista Pharmaceuticals, Inc. from 30 Apr 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
Summary
KalVista Pharmaceuticals, Inc. quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax in USD history and change rate from 30 Apr 2016 to 30 Sep 2025.
  • KalVista Pharmaceuticals, Inc. Accumulated Other Comprehensive Income (Loss), Net of Tax for the quarter ending 30 Sep 2025 was $6,729,000, a 149% decline year-over-year.
Source SEC data
View on sec.gov
Accumulated Other Comprehensive Income (Loss), Net of Tax, Quarterly (USD)
Accumulated Other Comprehensive Income (Loss), Net of Tax, YoY Quarterly Change (%)

KalVista Pharmaceuticals, Inc. Quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,729,000 -$4,028,000 -149% 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $6,387,000 -$3,518,000 -123% 31 Jul 2025 10-Q 11 Sep 2025 2026 Q1
Q1 2025 $5,214,000 -$1,726,000 -49% 30 Apr 2025 10-Q 11 Sep 2025 2026 Q1
Q4 2024 $2,418,000 +$876,000 +27% 31 Dec 2024 10-Q 10 Nov 2025 2025 Q3
Q3 2024 $2,701,000 +$764,000 +22% 31 Oct 2024 10-Q 05 Dec 2024 2025 Q2
Q2 2024 $2,869,000 +$22,000 +0.76% 31 Jul 2024 10-Q 05 Sep 2024 2025 Q1
Q1 2024 $3,488,000 -$428,000 -14% 30 Apr 2024 10-K 10 Jul 2025 2025 FY
Q4 2023 $3,294,000 +$247,000 +7% 31 Jan 2024 10-Q 11 Mar 2024 2024 Q3
Q3 2023 $3,465,000 +$1,861,000 +35% 31 Oct 2023 10-Q 07 Dec 2023 2024 Q2
Q2 2023 $2,891,000 +$1,259,000 +30% 31 Jul 2023 10-Q 07 Sep 2023 2024 Q1
Q1 2023 $3,060,000 +$801,000 +21% 30 Apr 2023 10-K 11 Jul 2024 2024 FY
Q4 2022 $3,541,000 -$1,202,000 -51% 31 Jan 2023 10-Q 09 Mar 2023 2023 Q3
Q3 2022 $5,326,000 -$3,606,000 -210% 31 Oct 2022 10-Q 08 Dec 2022 2023 Q2
Q2 2022 $4,150,000 -$2,661,000 -179% 31 Jul 2022 10-Q 08 Sep 2022 2023 Q1
Q1 2022 $3,861,000 -$2,429,000 -170% 30 Apr 2022 10-K 10 Jul 2023 2023 FY
Q4 2021 $2,339,000 -$1,072,000 -85% 31 Jan 2022 10-Q 10 Mar 2022 2022 Q3
Q3 2021 $1,720,000 +$236,000 +12% 31 Oct 2021 10-Q 09 Dec 2021 2022 Q2
Q2 2021 $1,489,000 +$130,000 +8% 31 Jul 2021 10-Q 09 Sep 2021 2022 Q1
Q1 2021 $1,432,000 +$450,000 +24% 30 Apr 2021 10-K 07 Jul 2022 2022 FY
Q4 2020 $1,267,000 +$115,000 +8.3% 31 Jan 2021 10-Q 11 Mar 2021 2021 Q3
Q3 2020 $1,956,000 -$492,000 -34% 31 Oct 2020 10-Q 10 Dec 2020 2021 Q2
Q2 2020 $1,619,000 +$368,000 +19% 31 Jul 2020 10-Q 14 Sep 2020 2021 Q1
Q1 2020 $1,882,000 +$44,000 +2.3% 30 Apr 2020 10-K 13 Jul 2021 2021 FY
Q4 2019 $1,382,000 +$719,000 +34% 31 Jan 2020 10-Q 10 Mar 2020 2020 Q3
Q3 2019 $1,464,000 +$772,000 +35% 31 Oct 2019 10-Q 03 Dec 2019 2020 Q2
Q2 2019 $1,987,000 +$442,000 +18% 31 Jul 2019 10-Q 09 Sep 2019 2020 Q1
Q1 2019 $1,926,000 -$817,000 -74% 30 Apr 2019 10-K 01 Jul 2020 2020 FY
Q4 2018 $2,101,000 -$1,965,000 -1445% 31 Jan 2019 10-Q 14 Mar 2019 2019 Q3
Q3 2018 $2,236,000 +$335,000 +13% 31 Oct 2018 10-Q 14 Dec 2018 2019 Q2
Q2 2018 $2,429,000 +$99,000 +3.9% 31 Jul 2018 10-Q 14 Sep 2018 2019 Q1
Q1 2018 $1,109,000 +$1,534,000 +58% 30 Apr 2018 10-K 16 Jul 2019 2019 FY
Q4 2017 $136,000 +$2,771,000 +95% 31 Jan 2018 10-Q 16 Mar 2018 2018 Q3
Q3 2017 $2,571,000 31 Oct 2017 10-Q 14 Dec 2017 2018 Q2
Q2 2017 $2,528,000 31 Jul 2017 10-Q 14 Sep 2017 2018 Q1
Q1 2017 $2,643,000 -$2,568,000 -3424% 30 Apr 2017 10-K 30 Jul 2018 2018 FY
Q4 2016 $2,907,000 31 Jan 2017 10-Q 16 Mar 2017 2016 Q3
Q1 2016 $75,000 30 Apr 2016 10-K 27 Jul 2017 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.